Logo

Insights+: EMA Marketing Authorization of New Drugs in September 2022

Share this

Insights+: EMA Marketing Authorization of New Drugs in September 2022

  • The EMA approved 7 New Chemical Entity (NCE) and 4 Biologic Drugs in Sept 2022, leading to treatments for patients and advances in the healthcare industry
  • In September 2022, the major highlights drugs were Imcivree approval for bardet-biedl syndrome, Opdualag for unresectable or metastatic melanoma, Ultomiris for generalised myasthenia gravis
  • PharmaShots has compiled a list of a total of 11 new drugs approved by the EMA in September 2022

 

1. Rhythm’s Imcivree (setmelanotide) Receives EC’s Approval for the Treatment of Bardet-Biedl Syndrome

Imcivree

Active ingredient: setmelanotide                                                   Approved: September 06, 2022

Company: Rhythm                                                                           Disease: Bardet-Biedl Syndrome

  • The EC has approved Imcivree for the treatment of obesity and control of hunger associated with genetically confirmed BBS in adult & pediatric patients (≥6yrs.) with impairments in the MC4R pathway due to genetic diseases
  • The expansion of Imcivree has led to the eligibility of Rhythm to receive an additional investment of $37.5M under the Revenue Interest Agreement with HealthCare Royalty & remains eligible to receive an additional investment amount of $25M payable upon achievement of agreed sales milestones in 2023
  • Additionally, Imcivree has received a Priority Review from Health Canada for the treatment of obesity & control of hunger in BBS, biallelic POMC, PCSK1, or LEPR deficiency

2. Kite’s Tecartus Receives EC’s Approval for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Tecartus

Active ingredient: brexucabtagene autoleucel                      Approved: September 07, 2022

Company: Kite                                                                          Disease: Acute Lymphoblastic Leukemia

  • The approval was based on the P-I/II (ZUMA-3) study in adult patients aged 18yrs. with ALL whose disease is refractory or relapsed, following standard systemic therapy or HSCT
  • The results showed that 71% of the evaluable patients achieved CR or CR with CRi with a median follow-up of 26.8mos., m-OS was 25.4mos. and 47mos. for responders (patients who achieved CR or CRi) & m-DoR was 18.6mos. in an efficacy-evaluable patients
  • The safety results were consistent with the known safety profile for Tecartus while grade ≥3 CRS and neurologic adverse reactions were reported in 25% and 32% of patients, and the therapy was generally well managed. The therapy marks the first approved treatment option for patients

3. Lytix Biopharma’s LTX-315 Receives EC’s Approval to Initiate P-II (ATLAS-IT-05) Study for Advanced Melanoma in EU

LTX-315

Active ingredient: brexucabtagene autoleucel                                   Approved: September 07, 2022

Company: Lytix Biopharma                                                                  Disease: Advanced Melanoma

  • The EC has granted approval to initiate the P-II (ATLAS-IT-05) study in 3 EU countries to evaluate LTX-315 + pembrolizumab for advanced melanoma. The study is currently ongoing in the US, initiated in 2021 at MD Anderson Cancer Center. Patients’ enrolment is ongoing & is expected to be completed in early 2023
  • The study purposes are to determine the effectiveness of LTX-315 + pembrolizumab in inducing responses for patients who have failed prior anti-PD 1/PD L1 immune checkpoint therapy
  • In 3 EU countries, the study will take place at highly recognized sites with intratumoral immunotherapy experience. The same procedures as in the US will be followed, and each site will be overseen by melanoma experts

4. BMS’ Opdualag (nivolumab and relatlimab) Receives EC’s Approval as 1L Treatment for Unresectable or Metastatic Melanoma

Opdualag

Active ingredient: nivolumab and relatlimab                  Approved: September 19, 2022

Company: BMS                                                                  Disease: Unresectable or Metastatic Melanoma

  • The approval was based upon an exploratory analysis from the P-II/III (RELATIVITY-047) evaluating the fixed-dose combination of nivolumab (480mg) + relatlimab (160mg) vs nivolumab (480mg) alone in a ratio (1:1) in 714 patients aged 12yrs. with prior untreated metastatic or unresectable melanoma with tumor cell expression <1% across EU member states, Iceland, Liechtenstein & Norway
  • The results showed an m-PFS (6.7mos. vs 3.0mos.), m-OS has not yet been reached, and the incidence of grade 3-5 adverse reactions was 43% vs 35%. The trial also met its 1EPs of PFS in the all-comer population & no new safety events were observed
  • Opdualag is 1st approved LAG-3-blocking Ab combination for advanced melanoma in the EU

5. AstraZeneca's Evusheld (tixagevimab and cilgavimab) Receives EC’s Approval for the Treatment of COVID-19

Evusheld

Active ingredient: tixagevimab and cilgavimab                           Approved: September 20, 2022

Company: AstraZeneca                                                                  Disease: COVID-19

  • The EC has approved Evusheld in adults & adolescents aged ≥12yrs. with COVID‑19 who do not require supplemental oxygen & with a high risk of progressing to sev. COVID‑19
  • The approval was based on the P-III (TACKLE) trial evaluating Evusheld (300mg each, IM) vs PBO in a ratio (1:1) in 903 patients with COVID-19 who were symptomatic for ≤7 days
  • The results showed that 1 IM dose of Evusheld provides protection against progression to sev. COVID-19 or death from any cause, 90% were at high risk due to co-morbidities or age, 50% reduction in relative risk of progressing to sev. COVID-19 or death @29 Days in non-hospitalized patients; risk reduction (88% & 67%) within 3 & 5 days of symptom onset in pre-specified analyses, was well tolerated

6. Zydus Lifesciences' Nulibry Receives EC’s Marketing Authorization for the Treatment of Molybdenum Cofactor Deficiency Type A

Nulibry

Active ingredient: fosdenopterin                                Approved: September 20, 2022

Company: Zydus Lifesciences                                    Disease: Molybdenum Cofactor Deficiency Type A

  • The EC has granted marketing authorization for Nulibry to treat MoCD Type A. The EC decision was based on the efficacy & safety data of the Nulibry vs natural history study
  • The EC’s centralized marketing authorization will be valid in all EU member states, Iceland, Liechtenstein, and Norway. The regulatory filing to the MHRA is expected in the coming months
  • Nulibry is a cPMP substrate replacement therapy & was approved in the US in 2021 to reduce the risk of mortality in patients with MoCD Type A. In Mar 2022, Sentynl holds the global rights to Nulibry and is responsible for the ongoing development and commercialization in the US and also for developing, manufacturing, and commercializing fosdenopterin globally

7. Roche’s Vabysmo (faricimab) Receives EC’s Approval for Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema

Vabysmo

Active ingredient: faricimab                             Approved: September 20, 2022

Company: Roche                                               Disease: Diabetic Macular Edema

  • The approval was based on the 4 P-III studies (TENAYA & LUCERNE) in nAMD at 1yr. & (YOSEMITE & RHINE) in DME at ~2yr. evaluating Vabysmo vs aflibercept in 3220 patients
  • All studies met their 1EPs i.e., patients treated with Vabysmo administered at q4mos. achieved similar vision gains & anatomical improvements vs aflibercept (q2mos.). The 2EPs of (TENAYA & LUCERNE) and (YOSEMITE & RHINE) studies, (46% & 45% and 52% & 51%) were able to be treated q4mos. in 1yr. and (34% & 33% and 21% & 20%) at q3mos.
  • In (YOSEMITE & RHINE) study @2yr., patients achieved q4mos. dosing increased to 60% & 64% while 18% & 14% at q3mos., was well tolerated with a favorable benefit-risk profile, 33% & 21% achieved fewer median no. of inj. for nAMD & DME

8. Aurinia’s Lupkynis (voclosporin) Receives EC’s Approval for the Treatment of Lupus Nephritis

Lupkynis

Active ingredient: voclosporin                          Approved: September 20, 2022

Company: Aurinia                                               Disease: Lupus Nephritis

  • The EC has granted marketing authorization for Lupkynis in adults with active LN. The MHRA’s decision in Great Britain is expected in the coming weeks
  • The EC’s decision was based on the P-III (AURORA 1 & 2) study to evaluate Lupkynis which showed that voclosporin + MMF & low-dose corticosteroids led to superior complete renal response rates @52wks. over MMF and low-dose corticosteroids alone. The safety profile was comparable to MMF & low-dose corticosteroids alone
  • The centralized marketing authorization is valid in EU member states, Iceland, Liechtenstein, Norway & Northern Ireland. Under the agreement with Otsuka, Aurinia will receive a $30.0M EC approval-related milestones & is eligible to receive a regulatory & reimbursement milestone along with royalties

9. BridgeBio Pharma and Sentynl Therapeutics Receive EC’s Conditional Marketing Authorization for Nulibry (fosdenopterin) to Treat MoCD Type A

Nulibry

Active ingredient: fosdenopterin                        Approved: September 21, 2022

Company: BridgeBio Pharma                             Disease: MoCD Type A

  • The EC has granted marketing authorization for Nulibry as 1st therapy for the treatment of MoCD Type A. The therapy will be available to qualified patients through an early access program
  • The EC’s decision was based on the efficacy and safety data from the three clinical trials to evaluate the efficacy of Nulibry vs natural history study which showed that patients achieved a 7.1 times lower risk of death in the genotype-matched analysis with 86% vs 52% surviving @3yrs.
  • The EC's centralized marketing authorization is valid in all EU member states, Iceland, Liechtenstein, & Norway. A regulatory filing to the MHRA is expected in the coming months as part of the EC decision reliance procedure

10. Alnylam’s Amvuttra (vutrisiran) Receives EC’s Approval for the Treatment of Hereditary Transthyretin-mediated Amyloidosis

Amvuttra

Active ingredient: vutrisiran                           Approved: September 21, 2022

Company: Alnylam                                          Disease: Hereditary Transthyretin-mediated Amyloidosis

  • The EC has granted marketing authorization for Amvuttra to treat hATTR amyloidosis in adult patients with stage 1 or 2 polyneuropathy
  • The approval was based on the 18mos. results from the P-III (HELIOS-A) study evaluating Amvuttra. The trial met its 1EPs & 2EPs at 9 & 18mos. which showed improvement in signs & symptoms of hATTR amyloidosis with ≥50% of patients experiencing halting or reversal of polyneuropathy manifestations along with an encouraging safety & tolerability profile, improvement in mean change from baseline in mNIS+7 @18mos. over PBO from the P-III (APOLLO) study of patisiran
  • The therapy has received ODD in the EU & US for ATTR amyloidosis & in Japan for transthyretin type familial amyloidosis with polyneuropathy

11. AstraZeneca’s Ultomiris (ravulizumab) Receive EC’s Approval for the Treatment of Generalised Myasthenia Gravis

Ultomiris

Active ingredient: ravulizumab                              Approved: September 26, 2022

Company: AstraZeneca                                          Disease: Generalised Myasthenia Gravis

  • The EC has approved Ultomiris as an add-on to standard therapy for gMG in adult patients who are AChR Ab+
  • The EC’s decision was based on the P-III (CHAMPION-MG) trial evaluating Ultomiris in a ratio (1:1) in 175 adult patients with gMG across North America, EU, Asia-Pacific & Japan for 26wks. The results showed that the therapy was superior to PBO in the 1EPs of change from baseline in MG-ADL total score @26wk. clinical benefits were seen @60wks. in prolonged follow-up results from OLE
  • Reduction in treatment burden with dosing q8w & the results were published in NEJM Evidence, improvement in daily activities in patients with milder symptoms. The safety profiles were consistent with P-III trials in PNH & aHUS

Related Post: Insights+: EMA Marketing Authorization of New Drugs in August 2022


Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions